DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

NPPA sets retail prices for 41 drug combinations, including 18 variants of off-patent diabetes drug empagliflozin, following steep price drops post-patent expiry ...

The global veterinary dermatology market, valued at US$18.59 billion in 2024, is forecasted to grow at a robust CAGR of 8.5%, ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 26, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Global pharmaceutical giant Boehringer Ingelheim has signed a new five-year ... The firm develops and markets products for both human and animal health. OMD’s remit includes human and animal ...

ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying research workflows.

Boehringer Ingelheim and Tessellate Bio partner to develop first-in ... We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty ...

Boehringer Ingelheim has released data on its patient reach ... “As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal ...

It also offers animal healthcare products for swine, ruminant, poultry, horses, and pets, among others. The report provides information and insights into Boehringer Ingelheim' tech activities ...

Additionally, Cue Biopharma is eligible for royalty payments on future net sales of any resulting products ... research collaboration with Boehringer Ingelheim aimed at developing a new therapy ...